Answers are grounded in this paper and cite their sources.
In the short and longer terms, the Medicare Drug Price Negotiation Program should be evaluated based on four categories of outcomes: beneficiary access, prices and spending, promotion of value, and effects on innovation.
No takes yet. Share an insight, caveat, or question.
Laura Tollen (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: